BiopharmaceuticalsBiopharmaceuticals

News

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for “At-the-Market” Common Share Issuance Programs

News - Aeterna Zentaris today announced that its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission has been declared effective by the SEC. Under the shelf registration statement, the Company may offer and sell from time to time, in one or more public offerings in the United States, up to $50 million of common shares in one or more "at-the-market" distribution programs, during a 36-month period. The specifics of any particular ATM share issuance program, along with the terms and the use of proceeds of any such common shares offered by the Company will be determined at the time of any such offering and will be described in detail in a prospectus supplement or supplements filed with the SEC at the time of any such offerings.

Scientists identify protein linked to most common movement disorder

News - A team of researchers from Université Laval and CHU de Québec identified unusually high levels of a certain protein in the brains of people suffering from essential tremor (ET), a movement disorder that affects 4% of the adult population. The discovery, the details of which were published in the most recent edition of the journal Movement Disorders, could lead to an effective treatment for this neurological condition, which is 10 times more prevalent than Parkinson’s disease.

Nordic Life Science Pipeline Announces Appointment of a new CFO and Acting CMO

News - Nordic Life Science Pipeline is proud to announce the appointment of Mrs France Tardif as the new Chief Financial Officer of the company as well as of Dr. Kevin O’Connor, our new acting Chief Medical Officer.

$18.4 million investment to improve clinical research in cancer

News - The Quebec – Clinical Research Organization in Cancer (Q-CROC) was awarded a $9.2 million investment from the Quebec government over four years as part of the Fonds de partenariat pour un Québec innovant et en santé (FPQIS). This public-private partnership was formally announced on February 14th, 2014 by Mr. Nicolas Marceau, the Quebec Minister of Finance and Economy. Private partners from the pharmaceutical industry and SMEs are providing matching funds, for a total investment of $18.4 million.

Government of Canada Celebrates New Business-Led Research Network in Québec City

News - The Honourable Greg Rickford, Minister of State (Science and Technology), was in Québec City today to celebrate the new Business-Led Network of Centres of Excellence in Precision Therapeutics (PreThera Research). As a result of the 2014 Business-Led Networks of Centres of Excellence (BL-NCE) competition, PreThera Research was awarded $15 million. This support will enable the Network's researchers to apply their knowledge of biomarkers

Aeterna Zentaris: Presentations on Zoptarelin Doxorubicin and Disorazol Z Conjugates at Upcoming International Symposium on GnRH

News - Aeterna Zentaris announces that presentations on two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.

Atrium Innovations Inc. Receives Final Court Approval of Arrangement with the Permira Funds

News - Atrium Innovations announces that the Superior Court of Québec issued a final order approving the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium for cash consideration of $24.00 per common share by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding convertible debentures.

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

News - Aeterna Zentaris announces the closing of its previously announced public offering of 11.0 million units generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.

Université Laval and Roche team up to test promising compounds for several disorders of the brain, including autism spectrum disorders

News - Thanks to this joint initiative, Université Laval researcher Yves De Koninck and his team will be able to pursue the development of the many scientific discoveries and advances they have made in the last 10 years. Dr. De Koninck is a Professor in Université Laval’s Faculty of Medicine, Scientific Director of the Institut Universitaire en Santé Mentale de Québec, and an internationally renowned expert in the fields of neurology and neurophotonics.

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

News - Aeterna Zentaris announced the appointment of Richard Sachse, MD, PhD, as Senior Vice President, Chief Scientific Officer. Before joining Aeterna Zentaris, Dr. Sachse was Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Contacts

Jean-MichelGarroLife Sciences

More details

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page